89 related articles for article (PubMed ID: 32156196)
1. Retraction to: Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats.
Stroke; 2020 Apr; 51(4):e72. PubMed ID: 32156196
[No Abstract] [Full Text] [Related]
2. Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats.
Zhou HH; Tang Y; Zhang XY; Luo CX; Gao LY; Wu HY; Chang L; Zhu DY
Stroke; 2015 May; 46(5):1352-8. PubMed ID: 25851770
[TBL] [Abstract][Full Text] [Related]
3. Response to Letter Regarding Article, "Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats".
Zhou HH; Zhu DY
Stroke; 2015 Aug; 46(8):e193. PubMed ID: 26111894
[No Abstract] [Full Text] [Related]
4. Letter by Zuo and Xu Regarding Article, "Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats".
Zuo X; Xu E
Stroke; 2015 Aug; 46(8):e192. PubMed ID: 26111889
[No Abstract] [Full Text] [Related]
5. Cloning, expression, and purification of a recombinant Tat-HA-NR2B9c peptide.
Zhou HH; Zhang AX; Zhang Y; Zhu DY
Protein Expr Purif; 2012 Oct; 85(2):239-45. PubMed ID: 22944204
[TBL] [Abstract][Full Text] [Related]
6. Tat-HA-NR2B9c attenuate oxaliplatin-induced neuropathic pain.
Zhou HH; Zhang L; Zhang HX; Xu BR; Zhang JP; Zhou YJ; Qian XP; Ge WH
Exp Neurol; 2019 Jan; 311():80-87. PubMed ID: 30253135
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke.
Li R; Huang Y; Chen L; Zhou H; Zhang M; Chang L; Shen H; Zhou M; Su P; Zhu D
Nanomedicine; 2019 Jun; 18():380-390. PubMed ID: 30428334
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of polypeptide nanoparticle for treatment of traumatic brain injury.
Wu P; Zhao H; Gou X; Wu X; Zhang S; Deng G; Chen Q
Int J Nanomedicine; 2019; 14():4059-4069. PubMed ID: 31213815
[No Abstract] [Full Text] [Related]
9. Tat-NR2B9c prevents excitotoxic neuronal superoxide production.
Chen Y; Brennan-Minnella AM; Sheth S; El-Benna J; Swanson RA
J Cereb Blood Flow Metab; 2015 May; 35(5):739-42. PubMed ID: 25669908
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor.
Bråtane BT; Cui H; Cook DJ; Bouley J; Tymianski M; Fisher M
Stroke; 2011 Nov; 42(11):3265-70. PubMed ID: 21903963
[TBL] [Abstract][Full Text] [Related]
11. Delayed 2-h post-stroke administration of R18 and NA-1 (TAT-NR2B9c) peptides after permanent and/or transient middle cerebral artery occlusion in the rat.
Milani D; Cross JL; Anderton RS; Blacker DJ; Knuckey NW; Meloni BP
Brain Res Bull; 2017 Oct; 135():62-68. PubMed ID: 28964774
[TBL] [Abstract][Full Text] [Related]
12. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates.
Cook DJ; Teves L; Tymianski M
Sci Transl Med; 2012 Oct; 4(154):154ra133. PubMed ID: 23035045
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95.
Dykstra CM; Ratnam M; Gurd JW
J Neuropathol Exp Neurol; 2009 Jul; 68(7):823-31. PubMed ID: 19535989
[TBL] [Abstract][Full Text] [Related]
14. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors.
Cui H; Hayashi A; Sun HS; Belmares MP; Cobey C; Phan T; Schweizer J; Salter MW; Wang YT; Tasker RA; Garman D; Rabinowitz J; Lu PS; Tymianski M
J Neurosci; 2007 Sep; 27(37):9901-15. PubMed ID: 17855605
[TBL] [Abstract][Full Text] [Related]
15. Calmodulin kinase IV-dependent CREB activation is required for neuroprotection via NMDA receptor-PSD95 disruption.
Bell KF; Bent RJ; Meese-Tamuri S; Ali A; Forder JP; Aarts MM
J Neurochem; 2013 Jul; 126(2):274-87. PubMed ID: 23363435
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression.
Martel MA; Soriano FX; Baxter P; Rickman C; Duncan R; Wyllie DJ; Hardingham GE
Channels (Austin); 2009; 3(1):12-5. PubMed ID: 19221512
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
Tan X; Chen Y; Li J; Li X; Miao Z; Xin N; Zhu J; Ge W; Feng Y; Xu X
Neuroscience; 2015 Apr; 290():552-60. PubMed ID: 25665755
[TBL] [Abstract][Full Text] [Related]
18. TAT-PEP Enhanced Neurobehavioral Functional Recovery by Facilitating Axonal Regeneration and Corticospinal Tract Projection After Stroke.
Deng B; Li L; Gou X; Xu H; Zhao Z; Wang Q; Xu L
Mol Neurobiol; 2018 Jan; 55(1):652-667. PubMed ID: 27987133
[TBL] [Abstract][Full Text] [Related]
19. TAT-NEP1-40 as a novel therapeutic candidate for axonal regeneration and functional recovery after stroke.
Gou X; Wang Q; Yang Q; Xu L; Xiong L
J Drug Target; 2011 Feb; 19(2):86-95. PubMed ID: 20367026
[TBL] [Abstract][Full Text] [Related]
20. Stability of an anti-stroke peptide: driving forces and kinetics in chemical degradation.
Li R; Wang F; Chen L; Zhu S; Wu L; Jiang S; Xu Q; Zhu D
Int J Pharm; 2014 Sep; 472(1-2):148-55. PubMed ID: 24929015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
